COVID-19 (Prevention)
12
1
1
5
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Low Risk
Score: 5/100
0.0%
0 terminated out of 12 trials
100.0%
+13.5% vs benchmark
42%
5 trials in Phase 3/4
80%
4 of 5 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 5 completed trials
Clinical Trials (12)
A Study Evaluating MDX2301 in Healthy Adults and Adults at Higher Risk for Severe COVID-19.
A Study of Ad26.COV2.S and Influenza Vaccines in Healthy Adults
A Study of Ad26.COV2.S in Healthy Pregnant Participants (COVID-19)
A Study of Ad26.COV2.S in Adults (COVID-19)
A Study to Evaluate Dose Levels of Ad26.COV2.S Administered as a Two-dose Schedule in Healthy Adults
Safety, Tolerability, and Pharmacokinetics of Q-Griffithsin Intranasal Spray
PREVENT-COVID-19: A Q-Griffithsin Intranasal Spray
Hydroxychloroquine (HCQ) as Post Exposure Prophylaxis (PEP) for Prevention of COVID-19
Clinical Trial to Assess Safety and Immunogenicity of Gam-COVID-Vac Combined Vector Vaccine for Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-Сov-2) Infection
Study to Evaluate Efficacy, Immunogenicity and Safety of the Sputnik-Light
An Open Study on the Safety, Tolerability, and Immunogenicity of "Sputnik Light" Vaccine
Clinical Trial of Efficacy, Safety, and Immunogenicity of Gam-COVID-Vac Vaccine Against COVID-19